The present invention relates to fusion proteins suitable for use as a medicament or research tool. Therapeutic uses of the fusion proteins may include the prevention or treatment of acute or chronic inflammatory and immune system-driven organ and micro-vascular disorders, for example, acute kidney injury, acute myocardial infarction, acute respiratory distress or chronic obstructive pulmonary disease fibrosis and other organ injuries resulting from tissue trauma and acute and chronic injury.

The present invention provides an isolated nucleic acid comprising, operably linked to an heterologous transgene, at least two copies of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, said at least two copies being selected independently from one another.

The present invention provides an isolated nucleic acid comprising, operably linked to an heterologous transgene, at least two copies of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, said at least two copies being selected independently from one another.

The present invention provides oligopeptidic compounds comprising a first oligopeptidic component derived from SLAMF1 and a second oligopeptidic component which is a cell-penetrating peptide. The oligopeptidic compounds provided have been found unexpectedly to block signalling from TLR4, TLR7, TLR8 and TLR9 in response to stimulus by their ligands, and also to display an anti-proliferative effect on cancer cells. The oligopeptidic compounds provided may be used in therapy for conditions associated with overactive immune responses, such as sepsis, and for treatment of cancer.

A facilitated method for use in efficient delivery of a pharmaceutical composition over a tissue such as the blood brain barrier and into neurons in the CNS for the treatment of Alzheimer's disease in a mammal, including man is provided. The method is comprising the steps of administrating a therapeutically effective amount of the isolated recombinant Bri2 BRICHOS and lipid microbubbles and enables an increased amount of the isolated recombinant protein to reach the brain to efficiently combat Aβ42 neurotoxicity.

Furthermore, a method for use in enhanced delivery of proteins comprising Bri2 BRICHOS and variants thereof over the blood-brain barrier, facilitating treatment and/or diagnostics of Alzheimer's disease and other neurological diseases is described herein. The method is comprising the steps of administrating a therapeutically effective amount of proteins comprising Bri2 BRICHOS and variants thereof as a first protein moiety coupled to another (non-Bri2) second protein or polypeptide moiety and optionally lipid microbubbles, in the absence of ultrasound treatment.

A facilitated method for use in efficient delivery of a pharmaceutical composition over a tissue such as the blood brain barrier and into neurons in the CNS for the treatment of Alzheimer's disease in a mammal, including man is provided. The method is comprising the steps of administrating a therapeutically effective amount of the isolated recombinant Bri2 BRICHOS and lipid microbubbles and enables an increased amount of the isolated recombinant protein to reach the brain to efficiently combat Aβ42 neurotoxicity.

Furthermore, a method for use in enhanced delivery of proteins comprising Bri2 BRICHOS and variants thereof over the blood-brain barrier, facilitating treatment and/or diagnostics of Alzheimer's disease and other neurological diseases is described herein. The method is comprising the steps of administrating a therapeutically effective amount of proteins comprising Bri2 BRICHOS and variants thereof as a first protein moiety coupled to another (non-Bri2) second protein or polypeptide moiety and optionally lipid microbubbles, in the absence of ultrasound treatment.

The present disclosure relates extracellular vesicles, e.g., exosomes, comprising an antigen-binding moeity, e.g., a single-domain antigen-binding moeity, e.g., a vNAR, a VHH, or a fragment thereof, that specifically binds transferrin receptor, and methods of making and using the same.

The present invention relates to a cord blood plasma-derived exosome or a mimetic thereof and a pharmaceutical use thereof. More particularly, the present invention provides the use of a human cord blood plasma-derived exosome or an exosome mimetic that mimics the proteomic profile of the cord blood plasma-derived exosome for the improvement, prevention or treatment of various autoimmune diseases or wound healing.

The present invention relates to a vaccine composition which is form neutering or spaying an animal and comprises a recombinant protein in which cholera toxin B subunit (CTB) and gonadotropin-releasing hormone (GnRH) are fused. More specifically, provided are: a recombinant protein for neutering or spaying an animal and for inducing antibodies against GnRH; a recombinant vector for producing the recombinant protein; a vaccine composition for neutering or spaying an animal, the vaccine composition comprising the recombinant protein; and a method for neutering or spaying an animal by using the vaccine composition. The vaccine composition according to the present invention induces antibodies against GnRH in an individual, thereby atrophying the ovaries or testes thereof. Therefore, the present invention can, at low cost, a high level of safety, and with minimal side effects, replace surgical procedures for neutering and spaying, and be beneficially used to neuter or spay an animal.

Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.